Misplaced Pages

3K3A-Activated Protein C

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from 3K3A-APC) Experimental drug for the treatment of stroke Pharmaceutical compound
3K3A-Activated Protein C
Clinical data
Other names3K3A-APC
Routes of
administration		Intravenous
Legal status
Legal status
  • Investigational
Identifiers
CAS Number

3K3A-Activated Protein C (3K3A-APC) is an experimental drug for the treatment of stroke developed by ZZ Biotech. It is also being assessed for the treatment of Alzheimer's disease. It is the subject of RHAPSODY, a phase II trial to determine safety and tolerability.

A phase III trial, RHAPSODY-2, to determine safety and efficacy for treatment of ischemic stroke, is planned. However, on November 16, 2023, the National Institutes of Health (NIH) paused the start of the human trial of 3K3A-APC after an investigation by Science Magazine.

The drug was designed to have more activity at protease-activated receptor 1 (PAR-1) and less anticoagulative effect than activated protein C.

References

  1. "First Patients Dosed in Phase 2 Trial of 3K3A-APC in ALS". Neurology live. 2021-12-03. Retrieved 2023-12-01.
  2. "3K3A-Activated Protein C (3K3A-APC)" (PDF). alzdiscovery.org. April 1, 2019.
  3. Lyden, Patrick; Pryor, Kent E.; Coffey, Christopher S.; Cudkowicz, Merit; Conwit, Robin; Jadhav, Ashutosh; Sawyer, Robert N.; Claassen, Jan; Adeoye, Opeolu; Song, Shlee; Hannon, Peter; Rost, Natalia S.; Hinduja, Archana; Torbey, Michel; Lee, Jin-Moo (January 2019). "Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke". Annals of Neurology. 85 (1): 125–136. doi:10.1002/ana.25383. ISSN 1531-8249. PMC 6342508. PMID 30450637.
  4. "Efficacy and Safety Evaluation of 3K3A-APC in Ischemic Stroke (RHAPSODY-2)". clinicaltrials.gov. Retrieved 2023-12-02.
  5. Piller, Charles (2023-12-02). "NIH puts hold on $30 million trial of potential stroke drug". Science. Archived from the original on 2023-12-02. Retrieved 2023-12-02.
  6. Lyden, Patrick; Levy, Howard; Weymer, Sara; Pryor, Kent; Kramer, William; Griffin, John H.; Davis, Thomas P.; Zlokovic, Berislav (2013). "Phase 1 Safety, Tolerability and Pharmacokinetics of 3K3A-APC in Healthy Adult Volunteers". Current Pharmaceutical Design. 19 (42): 7479–7485. doi:10.2174/1381612819666131230131454. ISSN 1381-6128. PMC 4040367. PMID 24372304.


Stub icon

This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it.

Categories: